<DOC>
	<DOCNO>NCT00437372</DOCNO>
	<brief_summary>This study use combination radiation antiangiogenic agent ( agent destroy exist blood vessel ) seem approach tumor cure .</brief_summary>
	<brief_title>Phase IB Study Using Sunitinib Plus Radiation Therapy Cancer Patients</brief_title>
	<detailed_description>The combination ionize radiation antiangiogenic agent seem counterintuitive approach tumor cure oxygen potent radiosensitizer reduction oxygen concentration would expect follow reduction tumor vasculature antiangiogenic treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Thoracic Neoplasms</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Minimum 2 week course radiation therapy Solid tumor central nervous system , head neck , thorax , pelvis Major surgery radiation therapy within 4 week start study treatment Grade 3 hemorrhage within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>central nervous system</keyword>
	<keyword>head neck</keyword>
	<keyword>thorax</keyword>
	<keyword>pelvic area</keyword>
</DOC>